PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 2011 October; 85(19): 10399–10403.
PMCID: PMC3196433

Circulating Monocytes Are Not a Major Reservoir of HIV-1 in Elite Suppressors[down-pointing small open triangle]

Abstract

Circulating HIV-1-infected monocytes have been identified in patients on highly active antiretroviral therapy and may represent an important barrier to viral eradication. The nature of these cells in HIV-1-infected patients who maintain undetectable viral loads and preserved CD4+ T cell counts without antiretroviral therapy (known as elite controllers or elite suppressors [ES]) is unknown. We describe here infrequent recovery of proviral HIV-1 DNA from circulating monocytes relative to CD4+ T cells in ES, despite permissiveness of these cells to HIV-1 viral entry ex vivo. Thus, monocytes do not appear to be a major reservoir of HIV-1 in ES.

TEXT

Cells of the monocyte/macrophage lineage have long been recognized as targets of HIV-1 infection and contributors to disease pathogenesis (2022, 25, 42, 47, 50). CD4+ T cells and monocyte/macrophages both serve as HIV-1 reservoirs that preclude viral eradication in HIV-1-infected patients despite the ability of highly active antiretroviral therapy (HAART) to block replication and durably suppress plasma viral load (1, 6, 11, 12, 17, 18, 45, 61). These reservoirs can lead to a rebound in viremia if HAART is stopped (12), and in the case of HIV-1-infected macrophages may contribute to tissue inflammation and damage despite ongoing suppressive HAART (15, 48, 56). Circulating monocytes in the peripheral blood are relatively resistant to productive HIV-1 infection ex vivo prior to differentiation into tissue macrophages (38, 39, 52, 57), which are more permissive to HIV-1 infection and viral replication (2, 37, 58). Despite this finding, HIV-1-infected monocytes have been identified in the peripheral blood of viremic and HAART-treated patients (3, 9, 14, 19, 2628, 31, 33, 34, 36, 43, 49, 51, 53, 54, 62) and are thought to contribute to viral persistence (13, 32).

The mechanisms of virologic and immunologic control that allow a minority of HIV-1-infected individuals to maintain undetectable viral loads without antiretroviral therapy are not known. While low-level viral replication appears to occur in these patients, known as elite controllers or elite suppressors (ES) (40), the quantity of total (24, 30, 46) and integrated (23) proviral DNA and replication-competent HIV-1 (8) in circulating CD4+ T cells is small compared to HIV-1-infected patients on HAART. The frequency of HIV-1-infected monocytes in the peripheral blood of ES has not been determined, and the role HIV-1-infected macrophages play in viral persistence in ES is unknown. We demonstrate here that the frequency of circulating monocytes containing HIV-1 proviral DNA is much lower than the frequency of HIV-1-infected CD4+ T cells in a cohort of ES, despite evidence of permissiveness to HIV-1 entry in monocytes from ES ex vivo.

In order to obtain pure populations of CD4+ T cells and monocytes, peripheral blood was obtained from HIV-1-infected patients on HAART and ES according to an approved Institutional Review Board protocol, and Ficoll gradient centrifugation was performed. All participants had undetectable viral loads that were confirmed by commercial assays. The median CD4+ T cell count for patients on HAART was 593 cells per μl (interquartile range, 499 to 823), the median CD8+ T cell percentage was 44.3% (range, 35.2 to 57.3), the median time with an undetectable viral load was 3 years (interquartile range, 2 to 5), and the median number of years from diagnosis was 11 years (interquartile range, 5 to 14). For ES, the median CD4+ T cell count was 989 cells per μl (interquartile range, 735 to 1282), the median CD8+ T cell percentage was 31.5% (range, 15.4 to 54.3), and the median number of years from diagnosis was 11 years (interquartile range, 3 to 19). Flow cytometry was performed on peripheral blood mononuclear cells (PBMCs) from each patient group along with PBMCs from healthy non-HIV-infected donors. CD14+ monocytes and CD4+ T cells were isolated from PBMCs by using magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec). CD14+ cells then underwent magnetic bead depletion according to the manufacturer's instructions (Invitrogen) to remove remaining CD3+ cells. The CD4+ T cell suspension was incubated with mouse anti-human antibodies to CD8, CD14, CD16, and CD19, followed by addition of sheep anti-mouse magnetic beads and magnetic bead depletion. Flow cytometry was used to determine the purity of each cell population (in a representative monocyte population, 1.5% of cells are CD3+/CD14; in a representative CD4+ T cell population, 0.2% are CD14+ [data not shown]). These cells were lysed to obtain genomic DNA according to the manufacturer's instructions (Qiagen). Quantitative PCR (qPCR) was performed using long terminal repeat (LTR) primers to determine the frequency of proviral HIV-1 DNA in circulating CD4+ T cells and monocytes. Single-step qPCR was performed on each sample under previously published conditions (29). The proviral HIV-1 DNA copy number was calculated relative to the RNase P gene copy number (Applied Biosystems), which had been previously quantified with a standard curve. Nested PCR using previously described nef primers (4) was performed in replicates of four on sample aliquots containing genomic DNA from 105 cells and from 104 cells as a complementary, semiquantitative means of determining the frequency of HIV-1 proviral DNA. A separate in vitro viral entry assay was used to compare the relative permissiveness of each cell type to viral entry in each cell population, using a previously described protocol (10).

Flow cytometry performed on PBMCs of uninfected controls, patients on HAART, and ES demonstrated similar frequencies of CD14+ monocytes between uninfected donors and ES (median values, 5.38% versus 4.28%, respectively; P = 0.91) (Fig. 1B). There was a significantly higher percentage of circulating monocytes expressing CCR5 among ES than in uninfected donors or patients on HAART (7.43% versus 2.44% [uninfected] or 0.73 [HAART]; P = 0.001 for ES versus uninfected and P = 0.0001 for ES versus HAART) (Fig. 1C). The mean fluorescence intensity (MFI) of CCR5+ monocytes was similar between ES and uninfected donors (Fig. 1D). CD16+ monocytes, a subset of CD14+ cells shown to be more permissive to HIV-1 infection (16), were overrepresented in ES compared to uninfected controls (7.87% versus 3.44%; P = 0.06) and patients on HAART (7.87% versus 1.86%; P = 0.02) (Fig. 1E). There was no correlation between CD4+ T cell count or percentage or CD8+ T cell percentage and the percentage of CD14+ monocytes or CD14+ CD16+ monocytes in ES versus patients on HAART (data not shown).

Fig. 1.
Frequency and coreceptor expression of circulating CD14+ cells in ES compared to uninfected donors and HIV+ patients on HAART. (A) Representative flow cytometry plots identifying CD14+, CCR5+, and CD14+ CD16+ populations. (B) Percent CD3 CD14 ...

Quantitative PCR using LTR primers demonstrated that the level of HIV-1 proviral DNA in circulating monocytes was below the limit of detection of this assay in all 11 ES patients and 11 of 13 patients on HAART. Proviral DNA was also not detected in CD4+ T cells of 10 of 11 ES. In contrast, proviral DNA was easily amplified from CD4+ T cells in 8 of 13 patients on suppressive HAART regimens (Fig. 2).

Fig. 2.
Frequency of HIV-1 proviral DNA transcripts in circulating target cells, determined by qPCR with samples from 11 ES and 13 patients on HAART. qPCR using LTR primers was performed on DNA of 105 cells from purified populations of CD4+ T cells and monocytes ...

To further quantify the difference in the frequency of HIV-1-infected monocytes compared to CD4+ T cells in ES and patients on HAART, we utilized a second PCR methodology. We performed four replicates of a nested PCR with nef primers on DNA isolated from these two cell types obtained from patients in both groups (Fig. 3). While virus was amplified from at least one out of four aliquots of 105 CD4+ T cells in seven of the eight ES sampled, only one aliquot of 105 monocytes from a single ES was positive for virus (Fig. 3A).

Fig. 3.
Frequency of infected circulating target cells based on semiquantitative PCR with nef primers in ES and patients taking HAART. Nested PCR was performed with nef primers on four replicates of DNA from 105 cells (A) or 104 cells (B) isolated from purified ...

In patients on HAART, virus was obtained from at least 1 of 4 aliquots of 105 cells from all 10 patients when CD4+ T cells were analyzed and from 4 of 10 patients when monocytes were examined (Fig. 3A). In ES, virus could still be amplified from CD4+ T cell aliquots containing 1 log fewer cells (104 CD4+ T cells) in 5 out of 8 ES, whereas no virus was amplified in 104 monocyte aliquots in any ES (Fig. 3B). Virus was amplified with DNA from 104 CD4+ T cells in all 10 patients on HAART and from 1 out of 7 of these patients when using DNA from 104 monocytes (Fig. 3B). Thus, the frequency of infected circulating CD4+ T cells in both ES and patients on HAART appears to be at least 1 log higher than the frequency of HIV-1-infected monocytes.

Given the low recovery of HIV-1 proviral DNA from monocytes of ES patients, we investigated whether these cells are resistant to HIV-1 entry. Flow cytometry data (Fig. 1) demonstrated that a significant percentage of circulating monocytes in ES patients expressed the cell surface markers CCR5 and CD16, suggesting a phenotype conducive to viral infection. We made use of a previously described VPR-BlaM entry assay (10) and found that between 3 and 34% of monocytes were susceptible to HIV-1 entry among individuals; however, no difference with regard to viral entry susceptibility was observed between the three patient groups tested (ES patients, viremic patients, and uninfected controls) (Fig. 4). Thus, consistent with our recent findings in CD4+ T cells (44), resistance to viral entry does not explain the low frequency of virus present in ES monocytes.

Fig. 4.
Percentages of monocytes allowing HIV-1 entry ex vivo from uninfected donors, viremic patients, and ES. A previously described entry assay utilizing a Vpr-BlaM fusion protein was used to measure HIV-1 entry into purified populations of circulating CD14 ...

This is the first study to examine the frequency of infected monocytes in ES. We showed that among circulating target cells, monocytes contain a minimal amount of detectable proviral HIV-1 DNA compared to CD4+ T cells in ES, despite the permissiveness of monocytes to HIV-1 entry demonstrated ex vivo. CCR5 and CD16 expression levels on a fraction of monocytes from ES suggest that a subset of these cells may be permissive to infection, either as precursor cells in the bone marrow or in the circulation (16, 37). Based on the PCR results shown here, however, it appears that circulating monocytes are not a significant source of residual HIV-1 viremia in ES.

Previous studies have generally shown a lower frequency of infected circulating monocytes than CD4+ T cells in patients receiving HAART (3, 9, 14, 19, 2628, 31, 33, 34, 36, 43, 49, 51, 54, 62), although significant variability exists in these studies with regard to methodology, cell purity, and frequency of proviral DNA recovered. Our data suggest that a similar trend is present in ES, and we cannot rule out the possibility that the low level of infection we detected in monocytes was in fact due to contaminating CD4+ T cells.

One explanation for this phenomenon lies in the different half-lives of these cell types in the circulation: monocytes typically migrate into tissue after 72 h (35, 55, 59, 60), while CD4+ T cells recirculate in the peripheral blood. We have previously documented a marked discordance in HIV-1 sequence present in the plasma compared to that present in resting (4, 5, 7) and activated (41) CD4+ T cells in ES. One possible explanation for this finding is that monocytes are the source of plasma virus in these patients. Due to the very limited amount of HIV-1 proviral DNA recovered from the monocytes of ES, we were unable to perform the phylogenetic analysis required to test this hypothesis. However, our results support the conclusion that monocytes are infrequently HIV-1 infected compared to CD4+ T cells and are unlikely to significantly contribute to persistent, low-level viremia in ES.

Acknowledgments

This work was supported by NIH grant R01 AI080328 (J.N.B.).

Footnotes

[down-pointing small open triangle]Published ahead of print on 27 July 2011.

REFERENCES

1. Alexaki A., Liu Y., Wigdahl B. 2008. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6:388–400. [PMC free article] [PubMed]
2. Arfi V., et al. 2008. Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J. Virol. 82:6557–6565. [PMC free article] [PubMed]
3. Bagasra O., Pomerantz R. J. 1993. Human immunodeficiency virus type I provirus is demonstrated in peripheral blood monocytes in vivo: a study utilizing an in situ PCR. AIDS Res. Hum. Retrovir. 9:69–76. [PubMed]
4. Bailey J. R., Brennan T. P., O'Connell K. A., Siliciano R. F., Blankson J. N. 2009. Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J. Virol. 83:88–97. [PMC free article] [PubMed]
5. Bailey J. R., et al. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758–4770. [PMC free article] [PubMed]
6. Bailey J. R., et al. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441–6457. [PMC free article] [PubMed]
7. Bailey J. R., Williams T. M., Siliciano R. F., Blankson J. N. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203:1357–1369. [PMC free article] [PubMed]
8. Blankson J. N., et al. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81:2508–2518. [PMC free article] [PubMed]
9. Calcaterra S., Cappiello G., Di Caro A., Garbuglia A. R., Benedetto A. 2001. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART. J. Infect. 43:239–245. [PubMed]
10. Cavrois M., De Noronha C., Greene W. C. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151–1154. [PubMed]
11. Chun T. W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–188. [PubMed]
12. Chun T. W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193–13197. [PubMed]
13. Crowe S., Zhu T., Muller W. A. 2003. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 74:635–641. [PubMed]
14. Delobel P., et al. 2005. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS 19:1739–1750. [PubMed]
15. Duliost A., et al. 2009. High frequency of neurocognitive disorders in older HIV-infected patients despite a sustained virological and immunological response on cART: the Sigma Study, abstr. 459, p. 220. 16th Conf. Retrovir. Opportunistic Infect., Montreal, Canada. CROI, Alexandria, VA.
16. Ellery P. J., et al. 2007. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178:6581–6589. [PubMed]
17. Finzi D., et al. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512–517. [PubMed]
18. Finzi D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300. [PubMed]
19. Fulcher J. A., et al. 2004. Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J. Virol. 78:7883–7893. [PMC free article] [PubMed]
20. Gartner S., Markovits P., Markovitz D. M., Betts R. F., Popovic M. 1986. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 256:2365–2371. [PubMed]
21. Gartner S., et al. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219. [PubMed]
22. Giulian D., Vaca K., Noonan C. A. 1990. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250:1593–1596. [PubMed]
23. Graf E. H., et al. 2011. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog. 7:e1001300. [PMC free article] [PubMed]
24. Hatano H., et al. 2009. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 83:329–335. [PMC free article] [PubMed]
25. Ho D. D., Rota T. R., Hirsch M. S. 1986. Infection of monocyte/macrophages by human T lymphotropic virus type III. J. Clin. Invest. 77:1712–1715. [PMC free article] [PubMed]
26. Hufert F. T., et al. 1991. Progression of HIV-1 infection. Monitoring of HIV-1 DNA in peripheral blood mononuclear cells by PCR. Arch. Virol. 120:233–240. [PubMed]
27. Hufert F. T., von Laer D., Schramm C., Tarnok A., Schmitz H. 1989. Detection of HIV-1 DNA in different subsets of human peripheral blood mononuclear cells using the PCR. Rapid communication. Arch. Virol. 106:341–345. [PubMed]
28. Innocenti P., Ottmann M., Morand P., Leclercq P., Seigneurin J. M. 1992. HIV-1 in blood monocytes: frequency of detection of proviral DNA using PCR and comparison with the total CD4 count. AIDS Res. Hum. Retrovir. 8:261–268. [PubMed]
29. Julg B., et al. 2010. Infrequent recovery of HIV from but robust exogenous infection of activated CD4+ T cells in HIV elite controllers. Clin. Infect. Dis. 51:233–238. [PubMed]
30. Lambotte O., et al. 2005. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41:1053–1056. [PubMed]
31. Lambotte O., et al. 2000. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23:114–119. [PubMed]
32. Le Douce V., Herbein G., Rohr O., Schwartz C. 2010. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 7:32. [PMC free article] [PubMed]
33. Lewin S. R., et al. 1998. HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. AIDS 12:719–727. [PubMed]
34. McElrath M. J., Steinman R. M., Cohn Z. A. 1991. Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J. Clin. Invest. 87:27–30. [PMC free article] [PubMed]
35. Meuret G., Bammert J., Hoffmann G. 1974. Kinetics of human monocytopoiesis. Blood 44:801–816. [PubMed]
36. Mikovits J. A., Lohrey N. C., Schulof R., Courtless J., Ruscetti F. W. 1992. Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo. J. Clin. Invest. 90:1486–1491. [PMC free article] [PubMed]
37. Naif H. M., et al. 1998. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J. Virol. 72:830–836. [PMC free article] [PubMed]
38. Neil S., Martin F., Ikeda Y., Collins M. 2001. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J. Virol. 75:5448–5456. [PMC free article] [PubMed]
39. O'Brien W. A., et al. 1994. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol. 68:1258–1263. [PMC free article] [PubMed]
40. O'Connell K. A., Bailey J. R., Blankson J. N. 2009. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol. Sci. 30:631–637. [PubMed]
41. O'Connell K. A., et al. 2010. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J. Virol. 84:7018–7028. [PMC free article] [PubMed]
42. Orenstein J. M., Fox C., Wahl S. M. 1997. Macrophages as a source of HIV during opportunistic infections. Science 276:1857–1861. [PubMed]
43. Potter S. J., et al. 2004. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. J. Leukoc. Biol. 76:562–570. [PubMed]
44. Rabi S. A., et al. 2011. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J. Virol. 85:979–986. [PMC free article] [PubMed]
45. Redel L., et al. 2010. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J. Leukoc. Biol. 87:575–588. [PubMed]
46. Saez-Cirion A., et al. 2011. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 118:955–964. [PubMed]
47. Schmitt M. P., et al. 1990. Multiplication of human immunodeficiency virus in primary cultures of human Kupffer cells: possible role of liver macrophage infection in the physiopathology of AIDS. Res. Virol. 141:143–152. [PubMed]
48. Schnell G., Spudich S., Harrington P., Price R. W., Swanstrom R. 2009. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 5:e1000395. [PMC free article] [PubMed]
49. Schnittman S. M., et al. 1989. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308. [PubMed]
50. Schuitemaker H. 1994. Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis? J. Leukoc. Biol. 56:218–224. [PubMed]
51. Shen Y., et al. 1994. Blood monocytes from most human immunodeficiency virus type 1-infected patients do not carry proviral DNA. Clin. Diagn. Lab. Immunol. 1:531–537. [PMC free article] [PubMed]
52. Sonza S., et al. 1996. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70:3863–3869. [PMC free article] [PubMed]
53. Sonza S., et al. 2001. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15:17–22. [PubMed]
54. Spear G. T., et al. 1990. Analysis of lymphocytes, monocytes, and neutrophils from human immunodeficiency virus (HIV)-infected persons for HIV DNA. J. Infect. Dis. 162:1239–1244. [PubMed]
55. Tacke F., Randolph G. J. 2006. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 211:609–618. [PubMed]
56. Tozzi V., et al. 2007. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune Defic. Syndr. 45:174–182. [PubMed]
57. Triques K., Stevenson M. 2004. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J. Virol. 78:5523–5527. [PMC free article] [PubMed]
58. Weinberg J. B., Matthews T. J., Cullen B. R., Malim M. H. 1991. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J. Exp. Med. 174:1477–1482. [PMC free article] [PubMed]
59. Whitelaw D. M. 1972. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet. 5:311–317. [PubMed]
60. Whitelaw D. M., Bell M. F., Batho H. F. 1968. Monocyte kinetics: observations after pulse labeling. J. Cell Physiol. 72:65–71. [PubMed]
61. Wong J. K., et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291–1295. [PubMed]
62. Zhu T., et al. 2002. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76:707–716. [PMC free article] [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)